ClinicalTrials.gg
CompletedNCT04084769Updated Sep 15, 2025Results posted

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

A Phase 3 interventional study of Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine and Meningococcal Group B vaccine (Trumenba®) in Meningococcal Immunisation (Healthy Volunteers), sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 30 sites in 2 countries. Open to participants aged 13 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
570
Allocation
Randomized
Ages
13 Years to 26 Years
Sex
All
01

Study summary

Primary Objective:

To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine:

  • In Group 1 participants who were first vaccinated with 1 dose of MenACYW Conjugate vaccine 3-6 years before the booster dose.
  • In Group 2 participants who were first vaccinated with 1 dose of Menveo vaccine (meningococcal [Groups A, C, Y and W135] Oligosaccharide Diphtheria CRM197 Conjugate vaccine) 3-6 years before the booster dose.

Secondary Objective:

To describe:

  • The vaccine seroresponse, seroprotection (serum bactericidal assay using human complement [hSBA] titer greater than or equal to [>=]1:8), and antibody responses (geometric mean titers [GMTs]) of meningococcal serogroups A, C, Y, and W measured using hSBA in serum specimens collected 6 days (±1 day) after vaccination in a subset of 50 participants per group (Groups 1 and 2).
  • The vaccine seroresponse, seroprotection (hSBA titer >=1:8), and antibody responses (GMTs) to serogroups A, C, Y, and W measured using hSBA on Day (D)0 (pre-vaccination) and D30 (+14 days) after vaccination with MenACYW Conjugate vaccine alone (Groups 1 and 2).
  • The antibody persistence (GMTs and vaccine seroprotection; hSBA titer >=1:8) of meningococcal serogroups A, C, Y, and W before a booster dose in participants who received either MenACYW Conjugate vaccine or Menveo vaccine 3-6 years earlier.
  • The antibody persistence (GMTs and vaccine seroprotection; hSBA titer >=1:8) of meningococcal serogroups A, C, Y, and W in participants who received either a single dose MenACYW Conjugate vaccine (participants randomized to MET59 Groups 1, 3, and 4) or Menveo vaccine (participants assigned to MET59 Group 2), as part of study MET50, or MET43 (participants randomized to MET59 Groups 1, 3 and 4).
  • To describe the vaccine seroresponse, seroprotection (hSBA titer >=1:8), and antibody responses (GMTs) to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with meningococcal serogroup B (MenB) vaccine (Groups 3 and 4), compared to those when it was given alone (Group 1).
Read the detailed description

Study duration per participant was approximately 6 months including: 1 day of screening and vaccination, 1 or 2 additional visits at Day 6 and Day 30, 2 phone calls and a safety follow-up/end of study visit, at Day 8 and Day 180 after vaccine administration, respectively.

Safety assessment included solicited reactions within 7 days after vaccination, unsolicited adverse events (AEs) up to 30 days after vaccination, serious adverse events (SAEs) throughout the study.

02

Conditions studied

  • Meningococcal Immunisation (Healthy Volunteers)
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged >= 13 to less than (\<) 26 years on the day of inclusion.
  • Participants participated in and completed study MET50 (MET50 Groups 1, 2, or 3 only) or study MET43 (MET43 Groups 1, 2, or 3 only).
  • For MET59 Group 2 only (Menveo vaccine-primed participants only; enrichment population): participants had a documented record of having received 1 dose of Menveo vaccine 3-6 years earlier either as part of a clinical trial or as routine vaccination. Participants who participated in MET50 Group 4 can be enrolled if they fulfill this criterion.
  • Participants aged 13 to \< 18 years: assent form had been signed and dated by the participant and form (ICF) had been signed and dated by the parent or guardian.
  • Participants aged >=18 (or legal age of majority, if different from 18 years of age) to \< 26 years: ICF had been signed and dated by the participants.
  • Participant aged 13 to \< 18 years: both the participant and parent or guardian were able to attend all scheduled visits and complied with all trial procedures.
  • Participants aged >=18 (or legal age of majority, if different from 18 years of age) to \< 26 years: able to attend all scheduled visits and complied with all trial procedures.

Exclusion criteria

Exclusion criteria:

  • Participant was pregnant, or lactating, or of and not using an effective method of or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination. To be considered of non-childbearing potential, a female must be pre-menarche, or for at least 1 year, or surgically sterile.
  • Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine before Visit 3 (Day 30) except for influenza vaccination, which might be received at least 2 weeks before study vaccine.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Receipt of any meningococcal vaccine including a licensed or investigational MenACWY vaccine or MenB vaccine since participation in study MET50 or MET43.
  • Menveo vaccine-primed participants only (enrichment group for Group 2): receipt of more than 1 dose of Menveo vaccine or vaccination with another licensed or investigational MenACWY vaccine or with a licensed or investigational MenB vaccine.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
  • Personal history of Guillain-Barré syndrome.
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
  • Verbal report of thrombocytopenia, contraindicating IM vaccination.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
  • Current alcohol abuse or drug addiction.
  • Chronic illness (e.g., Human immunodeficiency viruses, , ) that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >= 100.4 degree Fahrenheit). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
570 participants (actual)

Study arms

  • Experimental
    Group 1: MenACYW Conjugate vaccine

    Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).

    Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine

  • Experimental
    Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)

    Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).

    Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine

  • Experimental
    Group 3: MenACYW Conjugate vaccine + Trumenba vaccine

    Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).

    Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine · Biological: Meningococcal Group B vaccine (Trumenba®)

  • Experimental
    Group 4: MenACYW Conjugate vaccine + Bexsero vaccine

    Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).

    Biological: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine · Biological: Meningococcal group B vaccine (Bexsero®)

Interventions

  • BiologicalMeningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine

    Pharmaceutical form: Solution for injection Route of administration: IM

  • Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

    Also known as: Trumenba®

  • Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

    Also known as: Bexsero®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by Serum Bactericidal Assay Using Human Complement (hSBA). The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer greater than or equal to (\>=) 1:16 for participants with pre-vaccination hSBA titer less than (\<) 1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>= 1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.

    Time frame: Day 30 (post-vaccination) in study MET59

  2. Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 2

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.

    Time frame: Day 30 (post-vaccination) in study MET59

Secondary outcomes

  1. Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.

    Time frame: Day 6 (post-vaccination) in study MET59

  2. Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

    Time frame: Day 6 (post-vaccination) in study MET59

  3. Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

    GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

    Time frame: Day 6 (post-vaccination) in study MET59

  4. Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.

    Time frame: Day 30 (post-vaccination) in study MET59

  5. Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

    Antibody titers against meningococcal serogroups A, C, W, and Y were measured by hSBA. Seroprotection were defined as hSBA titer \>=1:8.

    Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59

  6. GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

    GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

    Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59

  7. Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

    Time frame: Day 0 (pre-vaccination) in study MET59

  8. GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0

    GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

    Time frame: Day 0 (pre-vaccination) in study MET59

  9. Percentage of Participants Achieving Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post-Vaccination in Study MET50 or MET43

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

    Time frame: Day 0 (pre-vaccination), Day 30 (post-vaccination) in study MET50 or MET43

  10. GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post Vaccination in Either Study MET50 or MET43 and Pre Vaccination in Study MET59

    GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

    Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET50 or MET43; Day 0 (pre-vaccination) in study MET59

  11. Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.

    Time frame: Day 30 (post-vaccination) in study MET59

  12. Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4

    Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

    Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59

  13. GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4

    GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

    Time frame: Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59

07

Results

Posted Aug 30, 2021

Participant flow

Study participants were enrolled from 03-September-2019 to 07-March-2020 at 30 active sites in the United States and Puerto Rico.

Participant flow — Overall Study
MilestoneGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero Vaccine
Started1911909594
Safety analysis set (safas)1861849392
Full analysis set1911909594
Per-protocol analysis set 1 (ppas1)464500
Per-protocol analysis set 2 (ppas2)1741769089
Completed1871869592
Not completed4402
Withdrew: Protocol violation1301
Withdrew: Withdrawal by subject0100
Withdrew: Withdrawal by parent/guardian1001
Withdrew: Lost to follow-up2000

Outcome measures

PrimaryPercentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by Serum Bactericidal Assay Using Human Complement (hSBA). The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer greater than or equal to (\>=) 1:16 for participants with pre-vaccination hSBA titer less than (\<) 1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>= 1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.

Time frame:
Day 30 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1
percentage of participantsGroup 1: MenACYW Conjugate Vaccine
Serogroup A94.8 (90.4 to 97.6)
Serogroup C97.1 (93.4 to 99.1)
Serogroup Y98.9 (95.9 to 99.9)
Serogroup W97.7 (94.2 to 99.4)
PrimaryPercentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 2

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Immune response was considered sufficient if lower limit of the 1-sided 97.5% CI for percentage of participants with hSBA seroresponse against serogroups A, C, Y and W was greater than 75%.

Time frame:
Day 30 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 2
percentage of participantsGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A93.2 (88.4 to 96.4)
Serogroup C98.9 (96.0 to 99.9)
Serogroup Y100 (97.9 to 100)
Serogroup W98.9 (96.0 to 99.9)
SecondaryPercentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.

Time frame:
Day 6 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A82.6 (68.6 to 92.2)77.8 (62.9 to 88.8)
Serogroup C89.1 (76.4 to 96.4)93.3 (81.7 to 98.6)
Serogroup Y95.7 (85.2 to 99.5)91.1 (78.8 to 97.5)
Serogroup W97.8 (88.5 to 99.9)88.9 (75.9 to 96.3)
SecondaryPercentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

Time frame:
Day 6 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A91.3 (79.2 to 97.6)95.6 (84.9 to 99.5)
Serogroup C100 (92.3 to 100)97.8 (88.2 to 99.9)
Serogroup Y97.8 (88.5 to 99.9)100 (92.1 to 100)
Serogroup W100 (92.3 to 100)100 (92.1 to 100)
SecondaryGeometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame:
Day 6 (post-vaccination) in study MET59
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
titersGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A289 (133 to 625)161 (93.0 to 280)
Serogroup C3799 (2504 to 5763)919 (500 to 1690)
Serogroup Y1658 (973 to 2826)800 (467 to 1371)
Serogroup W1928 (1187 to 3131)708 (463 to 1082)
SecondaryPercentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>=4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.

Time frame:
Day 30 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A94.8 (90.4 to 97.6)93.2 (88.4 to 96.4)
Serogroup C97.1 (93.4 to 99.1)98.9 (96.0 to 99.9)
Serogroup Y98.9 (95.9 to 99.9)100 (97.9 to 100)
Serogroup W97.7 (94.2 to 99.4)98.9 (96.0 to 99.9)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) · Difference in percentage: 1.65 · 95% CI -3.58 to 6.95
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) · Difference in percentage: -1.74 · 95% CI -5.50 to 1.60
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) · Difference in percentage: -1.15 · 95% CI -4.09 to 1.14
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed) · Difference in percentage: -1.16 · 95% CI -4.72 to 2.07
SecondaryPercentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

Antibody titers against meningococcal serogroups A, C, W, and Y were measured by hSBA. Seroprotection were defined as hSBA titer \>=1:8.

Time frame:
Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A: Day 071.3 (63.9 to 77.9)71.0 (63.7 to 77.6)
Serogroup A: Day 3099.4 (96.8 to 100)99.4 (96.9 to 100)
Serogroup C: Day 087.9 (82.1 to 92.4)50.6 (42.9 to 58.2)
Serogroup C: Day 30100 (97.9 to 100)100 (97.9 to 100)
Serogroup Y: Day 079.9 (73.2 to 85.6)52.8 (45.2 to 60.4)
Serogroup Y: Day 30100 (97.9 to 100)100 (97.9 to 100)
Serogroup W: Day 086.2 (80.2 to 91.0)77.8 (71.0 to 83.7)
Serogroup W: Day 30100 (97.9 to 100)100 (97.9 to 100)
SecondaryGMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame:
Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
Reported as:
Geometric mean · titers
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and at Day 30 Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1 and 2
titersGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A: Day 011.7 (9.89 to 13.8)11.5 (9.72 to 13.7)
Serogroup A: Day 30502 (388 to 649)399 (318 to 502)
Serogroup C: Day 036.6 (28.8 to 46.7)10.2 (8.03 to 13.0)
Serogroup C: Day 303708 (3146 to 4369)2533 (2076 to 3091)
Serogroup Y: Day 020.5 (16.6 to 25.2)8.35 (6.70 to 10.4)
Serogroup Y: Day 302308 (1925 to 2767)3036 (2547 to 3620)
Serogroup W: Day 027.0 (22.0 to 33.1)14.8 (12.2 to 18.1)
Serogroup W: Day 302290 (1934 to 2711)2574 (2178 to 3041)
SecondaryPercentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

Time frame:
Day 0 (pre-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero Vaccine
Serogroup A72.3 (65.3 to 78.5)71.1 (64.0 to 77.4)73.7 (63.6 to 82.2)73.1 (62.9 to 81.8)
Serogroup C86.9 (81.3 to 91.3)52.6 (45.3 to 59.9)86.3 (77.7 to 92.5)85.1 (76.3 to 91.6)
Serogroup Y79.1 (72.6 to 84.6)55.3 (47.9 to 62.5)88.3 (80.0 to 94.0)80.9 (71.4 to 88.2)
Serogroup W86.9 (81.3 to 91.3)77.9 (71.3 to 83.6)90.5 (82.8 to 95.6)91.4 (83.8 to 96.2)
SecondaryGMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame:
Day 0 (pre-vaccination) in study MET59
Reported as:
Geometric mean · titers
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0
titersGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero Vaccine
Serogroup A12.3 (10.5 to 14.5)12.2 (10.2 to 14.6)12.8 (10.0 to 16.3)12.7 (9.70 to 16.6)
Serogroup C34.5 (27.4 to 43.6)11.9 (9.17 to 15.3)38.4 (27.3 to 54.0)43.3 (29.8 to 63.0)
Serogroup Y19.8 (16.2 to 24.2)9.19 (7.39 to 11.4)26.0 (19.6 to 34.5)22.0 (16.1 to 30.0)
Serogroup W27.4 (22.4 to 33.4)15.1 (12.5 to 18.3)28.1 (21.8 to 36.2)32.7 (24.5 to 43.7)
SecondaryPercentage of Participants Achieving Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post-Vaccination in Study MET50 or MET43

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

Time frame:
Day 0 (pre-vaccination), Day 30 (post-vaccination) in study MET50 or MET43
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post-Vaccination in Study MET50 or MET43
percentage of participantsPooled Groups 1, 3 and 4: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A: Day 0 of MET50 or MET4354.5 (49.3 to 59.6)35.8 (27.7 to 44.6)
Serogroup A: Day 30 of MET50 or MET4394.7 (91.9 to 96.7)81.2 (73.5 to 87.5)
Serogroup C: Day 0 of MET50 or MET4318.6 (14.8 to 22.9)12.7 (7.6 to 19.5)
Serogroup C: Day 30 of MET50 or MET4398.1 (96.2 to 99.2)74.2 (65.9 to 81.5)
Serogroup Y: Day 0 of MET50 or MET434.5 (2.7 to 7.1)3.7 (1.2 to 8.5)
Serogroup Y: Day 30 of MET50 or MET4397.9 (95.9 to 99.1)88.7 (82.1 to 93.5)
Serogroup W: Day 0 of MET50 or MET4339.9 (34.9 to 45.0)40.3 (31.9 to 49.1)
Serogroup W: Day 30 of MET50 or MET43100 (99.0 to 100)93.2 (87.5 to 96.9)
SecondaryGMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post Vaccination in Either Study MET50 or MET43 and Pre Vaccination in Study MET59

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame:
Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET50 or MET43; Day 0 (pre-vaccination) in study MET59
Reported as:
Geometric mean · titers
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W at Day 0 and 30 Days Post Vaccination in Either Study MET50 or MET43 and Pre Vaccination in Study MET59
titersPooled Groups 1, 3 and 4: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)
Serogroup A: Day 0 of MET50 or MET437.28 (6.53 to 8.11)5.72 (4.75 to 6.87)
Serogroup A: Day 30 of MET50 or MET4345.2 (39.9 to 51.1)32.8 (25.0 to 43.1)
Serogroup A: Day 0 of MET5912.5 (11.1 to 14.1)11.6 (9.41 to 14.3)
Serogroup C: Day 0 of MET50 or MET433.48 (3.22 to 3.76)2.98 (2.69 to 3.30)
Serogroup C: Day 30 of MET50 or MET43417 (348 to 500)49.7 (32.4 to 76.4)
Serogroup C: Day 0 of MET5937.5 (31.6 to 44.5)11.0 (8.09 to 14.9)
Serogroup Y: Day 0 of MET50 or MET432.36 (2.22 to 2.50)2.30 (2.13 to 2.48)
Serogroup Y: Day 30 of MET50 or MET4391.0 (78.6 to 105)36.1 (27.2 to 47.8)
Serogroup Y: Day 0 of MET5921.8 (18.8 to 25.1)8.49 (6.50 to 11.1)
Serogroup W: Day 0 of MET50 or MET435.34 (4.76 to 6.00)5.54 (4.57 to 6.72)
Serogroup W: Day 30 of MET50 or MET4382.7 (73.6 to 92.9)45.1 (34.3 to 59.4)
Serogroup W: Day 0 of MET5928.8 (25.1 to 33.0)14.9 (11.9 to 18.6)
SecondaryPercentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. The hSBA vaccine seroresponse was defined as a post-vaccination hSBA titer \>=1:16 for participants with pre-vaccination hSBA titer \<1:8, or a \>= 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8.

Time frame:
Day 30 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero VaccinePooled Groups 3 and 4: MenACYW Conjugate Vaccine
Serogroup A94.8 (90.4 to 97.6)93.3 (86.1 to 97.5)95.5 (88.8 to 98.7)94.4 (89.9 to 97.3)
Serogroup C97.1 (93.4 to 99.1)97.8 (92.2 to 99.7)96.6 (90.4 to 99.3)97.2 (93.6 to 99.1)
Serogroup Y98.9 (95.9 to 99.9)98.9 (93.9 to 100)97.8 (92.1 to 99.7)98.3 (95.2 to 99.7)
Serogroup W97.7 (94.2 to 99.4)98.9 (94.0 to 100)96.6 (90.4 to 99.3)97.8 (94.3 to 99.4)
SecondaryPercentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4

Antibody titers against meningococcal serogroups A, C, Y, and W were measured by hSBA. Seroprotection was defined as hSBA titer \>=1:8.

Time frame:
Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
Reported as:
Number · percentage of participants
Percentage of Participants With Vaccine Seroprotection Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero VaccinePooled Groups 3 and 4: MenACYW Conjugate Vaccine
Serogroup A: Day 071.3 (63.9 to 77.9)73.3 (63.0 to 82.1)71.6 (61.0 to 80.7)72.5 (65.3 to 78.9)
Serogroup A: Day 3099.4 (96.8 to 100)98.9 (94.0 to 100)100 (95.9 to 100)99.4 (96.9 to 100)
Serogroup C: Day 087.9 (82.1 to 92.4)86.7 (77.9 to 92.9)86.5 (77.6 to 92.8)86.6 (80.7 to 91.2)
Serogroup C: Day 30100 (97.9 to 100)100 (96.0 to 100)100 (95.9 to 100)100 (97.9 to 100)
Serogroup Y: Day 079.9 (73.2 to 85.6)89.9 (81.7 to 95.3)80.9 (71.2 to 88.5)85.4 (79.3 to 90.2)
Serogroup Y: Day 30100 (97.9 to 100)100 (96.0 to 100)100 (95.9 to 100)100 (98.0 to 100)
Serogroup W: Day 086.2 (80.2 to 91.0)91.1 (83.2 to 96.1)90.9 (82.9 to 96.0)91.0 (85.8 to 94.8)
Serogroup W: Day 30100 (97.9 to 100)100 (96.0 to 100)100 (95.9 to 100)100 (98.0 to 100)
SecondaryGMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4

GMTs of antibodies against meningococcal serogroups A, C, Y, and W were measured by hSBA. Titers were expressed in terms of 1/dilution.

Time frame:
Day 0 (pre-vaccination) and Day 30 (post-vaccination) in study MET59
Reported as:
Geometric mean · titers
GMTs of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine in Study MET59: Group 1, 3 and 4
titersGroup 1: MenACYW Conjugate VaccineGroup 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero VaccinePooled Groups 3 and 4: MenACYW Conjugate Vaccine
Serogroup A: Day 011.7 (9.89 to 13.8)12.5 (9.78 to 16.0)12.3 (9.37 to 16.2)12.4 (10.4 to 14.9)
Serogroup A: Day 30502 (388 to 649)593 (426 to 825)667 (477 to 933)629 (498 to 794)
Serogroup C: Day 036.6 (28.8 to 46.7)37.6 (26.6 to 53.3)42.4 (29.4 to 61.0)39.9 (31.1 to 51.2)
Serogroup C: Day 303708 (3146 to 4369)4741 (3882 to 5791)3472 (2667 to 4518)4064 (3446 to 4793)
Serogroup Y: Day 020.5 (16.6 to 25.2)25.5 (19.4 to 33.6)21.0 (15.4 to 28.7)23.2 (18.9 to 28.5)
Serogroup Y: Day 302308 (1925 to 2767)2600 (2042 to 3311)2469 (1881 to 3241)2534 (2117 to 3034)
Serogroup W: Day 027.0 (22.0 to 33.1)28.3 (22.0 to 36.4)30.0 (22.5 to 40.1)29.1 (24.1 to 35.2)
Serogroup W: Day 302290 (1934 to 2711)2702 (2134 to 3422)2064 (1601 to 2662)2363 (1988 to 2810)

Adverse events

Collected over Unsolicited adverse event (AE) data were collected from Day 0 (pre-vaccination) up to Day 30 (post-vaccination) in MET59. The solicited reactions (SR) were collected within 7 days post-vaccination in MET59. Serious AEs data were collected up to 30 days post-vaccination in MET59.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MenACYW Conjugate Vaccine0/186 (0%)2/186 (1.1%)129/186 (69.4%)
Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)0/184 (0%)2/184 (1.1%)116/184 (63%)
Group 3: MenACYW Conjugate Vaccine + Trumenba Vaccine0/93 (0%)2/93 (2.2%)83/93 (89.2%)
Group 4: MenACYW Conjugate Vaccine + Bexsero Vaccine0/92 (0%)0/92 (0%)88/92 (95.7%)
Most frequent serious events
Most frequent serious events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero Vaccine
Accidental OverdoseInjury, poisoning and procedural complications0/1860/1841/930/92
Major DepressionPsychiatric disorders0/1860/1841/930/92
Suicidal IdeationPsychiatric disorders1/1861/1841/930/92
AppendicitisInfections and infestations1/1861/1840/930/92
Most frequent other events
Most frequent other events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero Vaccine
Injection Site PainGeneral disorders71/18663/18477/9385/92
MyalgiaMusculoskeletal and connective tissue disorders61/18664/18460/9358/92
HeadacheNervous system disorders68/18667/18441/9336/92
MalaiseGeneral disorders50/18647/18436/9337/92
Injection Site SwellingGeneral disorders10/1863/18412/9315/92
Injection Site ErythemaGeneral disorders12/18610/18415/9314/92
NasopharyngitisInfections and infestations9/1866/1845/932/92
Upper Respiratory Tract InfectionInfections and infestations10/1868/1841/931/92

Baseline characteristics

Analysis was performed on all enrolled participants.

Age, Continuous
Age, Continuous(years)Group 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero VaccineTotal
Mean15.4 ± 1.5915.8 ± 1.3715.1 ± 1.1215.3 ± 1.3415.4 ± 1.43
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero VaccineTotal
Female99854145270
Male921055449300
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)Group 3: MenACYW Conjugate Vaccine + Trumenba VaccineGroup 4: MenACYW Conjugate Vaccine + Bexsero VaccineTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander10012
Black or African American19167749
White1631658386497
More than one race865019
Unknown or Not Reported03003
08

Study locations

30 sites
  • Investigational Site Number 8400012
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 8400005
    San Diego, California 92123-1881, United States
  • Investigational Site Number 8400013
    Bardstown, Kentucky 40004, United States
  • Investigational Site Number 8400033
    Lexington, Kentucky 40517, United States
  • Investigational Site Number 8400034
    Bridgeton, Missouri 63044, United States
  • Investigational Site Number 8400027
    Lincoln, Nebraska 68504, United States
  • Investigational Site Number 8400002
    Lincoln, Nebraska 68505, United States
  • Investigational Site Number 8400004
    Lincoln, Nebraska 68516, United States
  • Investigational Site Number 8400030
    Dayton, Ohio 45414, United States
  • Investigational Site Number 8400028
    South Euclid, Ohio 44121, United States
  • Investigational Site Number 8400009
    Norman, Oklahoma 73069, United States
  • Investigational Site Number 8400038
    Erie, Pennsylvania 16505, United States
  • Investigational Site Number 8400039
    Charleston, South Carolina 29414, United States
  • Investigational Site Number 8400018
    Kingsport, Tennessee 37660, United States
  • Investigational Site Number 8400029
    Tullahoma, Tennessee 37388, United States
  • Investigational Site Number 8400031
    Kaysville, Utah 84037, United States
  • Investigational Site Number 8400001
    Layton, Utah 84041, United States
  • Investigational Site Number 8400014
    Layton, Utah 84041, United States
  • Investigational Site Number 8400040
    Orem, Utah 84057, United States
  • Investigational Site Number 8400011
    Provo, Utah 84064, United States
  • Investigational Site Number 8400023
    Roy, Utah 84067, United States
  • Investigational Site Number 8400003
    Salt Lake City, Utah 84107, United States
  • Investigational Site Number 8400007
    Salt Lake City, Utah 84109, United States
  • Investigational Site Number 8400022
    Salt Lake City, Utah 84109, United States
  • Investigational Site Number 8400015
    South Jordan, Utah 84095, United States
  • Investigational Site Number 8400036
    South Jordan, Utah 84095, United States
  • Investigational Site Number 8400032
    Syracuse, Utah 84075-9645, United States
  • Investigational Site Number 8400024
    West Jordan, Utah 84088-8865, United States
  • Investigational Site Number 8400037
    Charlottesville, Virginia 22903, United States
  • Investigational Site Number 6300001
    San Juan, 00981, Puerto Rico
09

References and documents

Publications

  • Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, Anez G, Shi J, Pan J, Hagenbach A, Von Barbier D, Varghese K, Jordanov E, Dhingra MS. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023 Sep;94(3):1035-1043. doi: 10.1038/s41390-023-02478-5. Epub 2023 Mar 10. PubMed 36899125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Sep 2020, 12 months.

Results were first posted in Aug 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 10, 2019
StartActual
Sep 3, 2019
Primary completionActual
Sep 14, 2020
CompletionActual
Sep 14, 2020
Results first posted
Aug 30, 2021
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04084769
Responsible party
Sponsor
First posted
Sep 10, 2019
Start date
Sep 3, 2019
Primary completion
Sep 14, 2020
Completion
Sep 14, 2020
Results posted
Aug 30, 2021
Last update
Sep 15, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion